Skip to main content
Premium Trial:

Request an Annual Quote

FDA Clears Newest Version of Celera's HIV-1 Genotyping Software

NEW YORK (GenomeWeb News) – Celera said today that the US Food and Drug Administration has granted marketing clearance for the firm’s ViroSeq HIV-1 Genotyping System Software v2.8.
 
The Alameda, Calif.-based firm’s HIV-1 Genotyping System detects mutations in the HIV-1 viral genome that confer resistance. It is used by physicians in monitoring and treating HIV-1 infections.
 
The newest version of the software includes the resistance algorithm for two new anti-HIV drugs, Intelence (etravirine) and Prezista (darunavir). It also includes an update of the resistance algorithm for all currently available protease and reverse transcriptase inhibitors, said Celera.
 
The ViroSeq system is manufactured by Celera and distributed by Abbott Laboratories.

The Scan

Could Mix It Up

The US Food and Drug Administration is considering a plan that would allow for the mixing-and-matching of SARS-CoV-2 vaccines and boosters, the New York Times says.

Closest to the Dog

New Scientist reports that extinct Japanese wolf appears to be the closest known wild relative of dogs.

Offer to Come Back

The Knoxville News Sentinel reports that the University of Tennessee is offering Anming Hu, a professor who was acquitted of charges that he hid ties to China, his position back.

PNAS Papers on Myeloid Differentiation MicroRNAs, Urinary Exosomes, Maize Domestication

In PNAS this week: role of microRNAs in myeloid differentiation, exosomes in urine, and more.